How to select a research topic that is appropriate for a clinician and that can lead to a peer-reviewed publication?In this essay,I will provide 5 tips:keep it interesting,keep it relevant,keep it inclusive,keep it si...How to select a research topic that is appropriate for a clinician and that can lead to a peer-reviewed publication?In this essay,I will provide 5 tips:keep it interesting,keep it relevant,keep it inclusive,keep it simple,and keep it trying.Keep it展开更多
AIM:To examine the determinants of maternal-neonatal transmission of hepatitis B virus(HBV) METHODS:A nested case-control study was conducted in Changsha,Hunan,People's Republic of China from January 1,2005 to Sep...AIM:To examine the determinants of maternal-neonatal transmission of hepatitis B virus(HBV) METHODS:A nested case-control study was conducted in Changsha,Hunan,People's Republic of China from January 1,2005 to September 31,2006 To avoid potential maternal blood contamination,we collected vein blood of newborns immediately after birth and before initial hepatitis B vaccination to determine the HBV infection status of the newborn For each HBsAg-positive infant,one HBsAg-negative infant born to an HBsAg-positive mother was matched by hospital at birth(same),gender(same),and date of birth(within 1 mo) A faceto-face interview was conducted to collect clinical and epidemiological data Conditional logistic regression analysis was used to estimate the independent effects of various determinants on maternal-neonatal transmission of HBV RESULTS:A total of 141 HBsAg-positive infants and 141 individually matched HBsAg-negative infants were included in the final analysis Maternal first-degree family history of HBV infection,intrahepatic cholestasis,and premature rupture of membranes were risk factors for perinatal transmission of HBV,whereas systematic treatment and HBV immunoglobulin injections for mothers with HBV infection were protective factors for maternal-neonatal transmission of HBV,after adjustment for potential confounding factors CONCLUSION:For HBsAg-positive mothers,systematic treatment,HBV immunoglobulin administration,and controlling intrahepatic cholestasis and pregnancy complications may reduce the incidence of perinatal transmission of HBV.展开更多
Objective: The purpose of this study was to identify the gestational age with the lowest morbidity and mortality rates for twin pregnancies that reach term. Study design: A retrospective cohort study carried out with ...Objective: The purpose of this study was to identify the gestational age with the lowest morbidity and mortality rates for twin pregnancies that reach term. Study design: A retrospective cohort study carried out with 60,443 twin pairs from the United States(1995-1997). Analysis was restricted to pregnancies that had reached at least 37 weeks of gestation; groups were created on the basis of the gestational ages of 37, 38, 39, and ≥40 weeks. The incidence of death and morbidity were calculated; multiple logistic regression models were used to estimate the independent effect of gestational age for twin A and B. Results: The neonatal mortality rate increased significantly after 40 weeks of gestation(twin A: odds ratio, 3.47 [95%CI, 2.29, 5.38]; twin B, odds ratio, 2.52 [95%CI, 1.75, 3.67]). There was also an increased risk of neonatal morbidity in the ≥40 weeks of gestation group for twin A and B(Apgar score, ≤3; odds ratio, 1.88 [95%CI, 1.18, 3.02], 1.74 [95%CI, 1.21, 2.52], respectively). There was a decreased risk of assisted ventilation in the 38 and 39 weeks of gestation group for twin A(odds ratio, 0.86 [95%CI, 0.77, 0.97], odds ratio, 0.83 [95%CI, 0.72, 0.95], respectively) and a decreased risk in the 39 and ≥40 weeks of gestation groups for twin B(assisted ventilation: odds ratio, 0.83 [95%CI, 0.73, 0.93], odds ratio, 0.81 [95%CI, 0.72, 0.92], respectively). Conclusion: This study suggests that the optimal date of delivery for twins should be< 40 weeks of gestation; there was no compelling evidence for delivering at< 38 weeks of gestation.展开更多
Background Changing health care providers frequently breaks the continuity of care,which is associated with many health care problems.The purpose of this study was to examine the association between a change of health...Background Changing health care providers frequently breaks the continuity of care,which is associated with many health care problems.The purpose of this study was to examine the association between a change of health care providers and pregnancy exposure to FDA category C,D and X drugs.Methods A 50% random sample of women who gave a birth in Saskatchewan between January 1,1997 and December 31,2000 were chosen for this study.The association between the number of changes in health care providers and with pregnancy exposure to category C,D,and X drugs for those women with and without chronic diseases were evaluated using multiple logistical regression,with adjusted odds ratios （ORs） and its 95% confidence intervals （C/s） as the association measures.Results A total of 18 568 women were included in this study.Rates of FDA C,D,and X drug uses were 14.35%,17.07%,21.72%,and 31.14%,in women with no change of provider,1-2 changes,3-5 changes,and more than 5 changes of health care providers.An association between the number of changes of health care providers and pregnancy exposure to FDA C,D,and X drugs existed in women without chronic diseases but not in women with chronic disease.Conclusion Change of health care providers is associated with pregnancy exposure to FDA category C,D and X drugs in women without chronic diseases.展开更多
文摘How to select a research topic that is appropriate for a clinician and that can lead to a peer-reviewed publication?In this essay,I will provide 5 tips:keep it interesting,keep it relevant,keep it inclusive,keep it simple,and keep it trying.Keep it
基金Supported by Hunan Ministry of Science and Technology,No.06FJ3177,China
文摘AIM:To examine the determinants of maternal-neonatal transmission of hepatitis B virus(HBV) METHODS:A nested case-control study was conducted in Changsha,Hunan,People's Republic of China from January 1,2005 to September 31,2006 To avoid potential maternal blood contamination,we collected vein blood of newborns immediately after birth and before initial hepatitis B vaccination to determine the HBV infection status of the newborn For each HBsAg-positive infant,one HBsAg-negative infant born to an HBsAg-positive mother was matched by hospital at birth(same),gender(same),and date of birth(within 1 mo) A faceto-face interview was conducted to collect clinical and epidemiological data Conditional logistic regression analysis was used to estimate the independent effects of various determinants on maternal-neonatal transmission of HBV RESULTS:A total of 141 HBsAg-positive infants and 141 individually matched HBsAg-negative infants were included in the final analysis Maternal first-degree family history of HBV infection,intrahepatic cholestasis,and premature rupture of membranes were risk factors for perinatal transmission of HBV,whereas systematic treatment and HBV immunoglobulin injections for mothers with HBV infection were protective factors for maternal-neonatal transmission of HBV,after adjustment for potential confounding factors CONCLUSION:For HBsAg-positive mothers,systematic treatment,HBV immunoglobulin administration,and controlling intrahepatic cholestasis and pregnancy complications may reduce the incidence of perinatal transmission of HBV.
文摘Objective: The purpose of this study was to identify the gestational age with the lowest morbidity and mortality rates for twin pregnancies that reach term. Study design: A retrospective cohort study carried out with 60,443 twin pairs from the United States(1995-1997). Analysis was restricted to pregnancies that had reached at least 37 weeks of gestation; groups were created on the basis of the gestational ages of 37, 38, 39, and ≥40 weeks. The incidence of death and morbidity were calculated; multiple logistic regression models were used to estimate the independent effect of gestational age for twin A and B. Results: The neonatal mortality rate increased significantly after 40 weeks of gestation(twin A: odds ratio, 3.47 [95%CI, 2.29, 5.38]; twin B, odds ratio, 2.52 [95%CI, 1.75, 3.67]). There was also an increased risk of neonatal morbidity in the ≥40 weeks of gestation group for twin A and B(Apgar score, ≤3; odds ratio, 1.88 [95%CI, 1.18, 3.02], 1.74 [95%CI, 1.21, 2.52], respectively). There was a decreased risk of assisted ventilation in the 38 and 39 weeks of gestation group for twin A(odds ratio, 0.86 [95%CI, 0.77, 0.97], odds ratio, 0.83 [95%CI, 0.72, 0.95], respectively) and a decreased risk in the 39 and ≥40 weeks of gestation groups for twin B(assisted ventilation: odds ratio, 0.83 [95%CI, 0.73, 0.93], odds ratio, 0.81 [95%CI, 0.72, 0.92], respectively). Conclusion: This study suggests that the optimal date of delivery for twins should be< 40 weeks of gestation; there was no compelling evidence for delivering at< 38 weeks of gestation.
文摘Background Changing health care providers frequently breaks the continuity of care,which is associated with many health care problems.The purpose of this study was to examine the association between a change of health care providers and pregnancy exposure to FDA category C,D and X drugs.Methods A 50% random sample of women who gave a birth in Saskatchewan between January 1,1997 and December 31,2000 were chosen for this study.The association between the number of changes in health care providers and with pregnancy exposure to category C,D,and X drugs for those women with and without chronic diseases were evaluated using multiple logistical regression,with adjusted odds ratios （ORs） and its 95% confidence intervals （C/s） as the association measures.Results A total of 18 568 women were included in this study.Rates of FDA C,D,and X drug uses were 14.35%,17.07%,21.72%,and 31.14%,in women with no change of provider,1-2 changes,3-5 changes,and more than 5 changes of health care providers.An association between the number of changes of health care providers and pregnancy exposure to FDA C,D,and X drugs existed in women without chronic diseases but not in women with chronic disease.Conclusion Change of health care providers is associated with pregnancy exposure to FDA category C,D and X drugs in women without chronic diseases.
